130 related articles for article (PubMed ID: 9565062)
21. Aldose reductase / polyol inhibitors for diabetic retinopathy.
Obrosova IG; Kador PF
Curr Pharm Biotechnol; 2011 Mar; 12(3):373-85. PubMed ID: 20939801
[TBL] [Abstract][Full Text] [Related]
22. Shedding light on blindness.
Barinapa M
Science; 1995 Jan; 267(5197):452-3. PubMed ID: 7824943
[No Abstract] [Full Text] [Related]
23. Effect of SG-210, a novel aldose reductase inhibitor, on impaired polyol pathway in rats received diabetic manipulations.
Horie S; Nagai H; Yuuki T; Narita Y; Tsuda Y; Nakajima T; Nakamura N
J Diabetes Complications; 1998; 12(3):163-9. PubMed ID: 9618072
[TBL] [Abstract][Full Text] [Related]
24. Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina in vivo.
Hattori T; Matsubara A; Taniguchi K; Ogura Y
Curr Eye Res; 2010 Feb; 35(2):146-54. PubMed ID: 20136425
[TBL] [Abstract][Full Text] [Related]
25. Sorbinil prevention of diabetic-like retinopathy in the galactose-fed rat model.
Robison WG; Laver NM; Jacot JL; Glover JP
Invest Ophthalmol Vis Sci; 1995 Nov; 36(12):2368-80. PubMed ID: 7591626
[TBL] [Abstract][Full Text] [Related]
26. [Vascular endothelial growth factor in the aqueous humor in diabetic retinopathy and other diseases of the retina].
Pfeiffer A
Dtsch Med Wochenschr; 1995 Oct; 120(42):1453. PubMed ID: 7555678
[No Abstract] [Full Text] [Related]
27. Prevention of VEGF-induced growth and tube formation in human retinal endothelial cells by aldose reductase inhibition.
Yadav UC; Srivastava SK; Ramana KV
J Diabetes Complications; 2012; 26(5):369-77. PubMed ID: 22658411
[TBL] [Abstract][Full Text] [Related]
28. Endothelial and glial cell interaction in diabetic retinopathy via the function of vascular endothelial growth factor (VEGF).
Sueishi K; Hata Y; Murata T; Nakagawa K; Ishibashi T; Inomata H
Pol J Pharmacol; 1996; 48(3):307-16. PubMed ID: 9112668
[TBL] [Abstract][Full Text] [Related]
29. Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy.
Gerhardinger C; Brown LF; Roy S; Mizutani M; Zucker CL; Lorenzi M
Am J Pathol; 1998 Jun; 152(6):1453-62. PubMed ID: 9626050
[TBL] [Abstract][Full Text] [Related]
30. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells.
Cheng T; Cao W; Wen R; Steinberg RH; LaVail MM
Invest Ophthalmol Vis Sci; 1998 Mar; 39(3):581-91. PubMed ID: 9501870
[TBL] [Abstract][Full Text] [Related]
31. Aldose reductase inhibition and retinopathy.
Robison WG
Diabetes; 1994 Feb; 43(2):337-9. PubMed ID: 8288059
[No Abstract] [Full Text] [Related]
32. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
Sun W; Oates PJ; Coutcher JB; Gerhardinger C; Lorenzi M
Diabetes; 2006 Oct; 55(10):2757-62. PubMed ID: 17003340
[TBL] [Abstract][Full Text] [Related]
33. VEGF and VEGF receptor levels in retinal and brain-derived endothelial cells.
Rajah TT; Grammas P
Biochem Biophys Res Commun; 2002 May; 293(2):710-3. PubMed ID: 12054527
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity.
Alon T; Hemo I; Itin A; Pe'er J; Stone J; Keshet E
Nat Med; 1995 Oct; 1(10):1024-8. PubMed ID: 7489357
[TBL] [Abstract][Full Text] [Related]
35. The polyol pathway in retinal microangiopathy.
Robison WG; Kinoshita JH; Kador PF
Drugs; 1986; 32 Suppl 2():19-22. PubMed ID: 3098542
[TBL] [Abstract][Full Text] [Related]
36. The galactosemic dog. A valid model for both early and late stages of diabetic retinopathy.
Frank RN
Arch Ophthalmol; 1995 Mar; 113(3):275-6. PubMed ID: 7887838
[No Abstract] [Full Text] [Related]
37. Genes and diabetic retinopathy.
Radha V; Rema M; Mohan V
Indian J Ophthalmol; 2002 Mar; 50(1):5-11. PubMed ID: 12090088
[TBL] [Abstract][Full Text] [Related]
38. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo.
Kuroki M; Voest EE; Amano S; Beerepoot LV; Takashima S; Tolentino M; Kim RY; Rohan RM; Colby KA; Yeo KT; Adamis AP
J Clin Invest; 1996 Oct; 98(7):1667-75. PubMed ID: 8833917
[TBL] [Abstract][Full Text] [Related]
39. Galactose-induced retinal microangiopathy in rats.
Kern TS; Engerman RL
Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):490-6. PubMed ID: 7843917
[TBL] [Abstract][Full Text] [Related]
40. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy.
Amin RH; Frank RN; Kennedy A; Eliott D; Puklin JE; Abrams GW
Invest Ophthalmol Vis Sci; 1997 Jan; 38(1):36-47. PubMed ID: 9008628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
